Nkf-Doqi Clinical Practice Guidelines for Peritoneal Dialysis Adequacy

Total Page:16

File Type:pdf, Size:1020Kb

Nkf-Doqi Clinical Practice Guidelines for Peritoneal Dialysis Adequacy NKF-DOQI CLINICAL PRACTICE GUIDELINES FOR PERITONEAL DIALYSIS ADEQUACY 867 Acronyms and Abbreviations Abbreviation Term ACE angiotensin-converting enzyme BSA body surface area BUN blood urea nitrogen concentration (an old term; SUN is technically correct, see below) CANUSA Canada/USA Peritoneal Dialysis Study CAPD continuous ambulatory peritoneal dialysis CCPD continuous cycling peritoneal dialysis CCr creatinine clearance CrCr residual renal creatinine clearance DI dialysis index DPI dietary protein intake eC effective clearance ESRD end-stage renal disease GFR glomerular filtration rate HD hemodialysis Kpcr peritoneal creatinine clearance KptlVurea the peritoneal component of KtIV urea KprtlVurea the sum of peritoneal and renal KtIV urea. These terms are interchangeable in that KtIVurea is total unless otherwise noted. KtlVurea urea clearance X time normalized by total body water, the volume of distribution of urea KrtlVurea the renal component of KtIV urea MTC mass transfer coefficient n normalized nBSA normalized body surface area NIPD nightly intermittent peritoneal dialysis nPCR normalized protein catabolic rate nPNA normalized protein equivalent of total nitrogen appearance nV normalized volume PCR protein catabolic rate PD peritoneal dialysis PET peritoneal equilibration test PNA protein equivalent of nitrogen appearance QOL quality of life RRF residual renal function SGA subjective global assessment SHR standardized hospitalization rates SUN serum urea nitrogen concentration t time UKM urea kinetic modeling UNA urea nitrogen appearance URR urea reduction ratio USRDS United States Renal Data System V volume of distribution. When referring to urea, this is total body water S68 Introduction This Work Group was charged with preparing purpose of these guidelines, a child was considered practice guidelines for the "adequacy of perito• to be a' patient less than 19 years of age. neal dialysis," a topic which could be defined An "effective dose" is that which achieves its broadly or narrowly. The Work Group elected to stated goal. That goal is some form of outcome focus its guidelines on those areas of "ade• measure(s), and could be determined by patient, quacy" that needed the most urgent develop• provider, payer, regulator or a combination of ment, knowing that subsequent guidelines will these parties. At the lower extreme is the' 'mini• be developed or that others were currently under mal effective dose." In certain circumstances this development (e.g., for management of peritoni• may be interpreted as "adequate," At the other tis). In addition, the Work Group focused on top• extreme is the "maximal effective dose," the ics for which guidelines would likely have the dose above which there are no additional bene• greatest impact on patient outcomes. However, fits. For hemodialysis and peritoneal dialysis the the Work Group's focus should not be construed maximal effective dose is not known. Some• to mean that areas not covered are unimportant. where between these extremes is the "optimal Some external reviewers criticized these dose," the dose above which the additional de• guidelines as too complex, while others wrote rived benefit does not justify the additional cost that they were not thorough enough. Some or burden. If one accepts this definition, the Work wanted guidelines merged, and others thought Group intended to more precisely define "opti• the guidelines were too dense. The Work Groop mal dose" targets in a clinically relevant and considered all these issues. quantitative fashion. It was the intention of the We advise the reader to first become familiar Work Group to bring "adequate dose" to the with the Table of Contents, which provides a level of "optimal dose" by raising the outcome listing of the Clinical Practice Guidelines for goals or expectations. The present guidelines at• Peritoneal Dialysis Adequacy; detailed rationales tempt to make recommendations based on avail• are provided for each guideline. Redundancies able scientific/medical evidence, resorting to ex• are often intentional because it is anticipated that pert opinion only when necessary. It is clearly a reader might review only selected topics. How• stated in each guideline title when recommenda• ever, the Work Group considers these guidelines tions were based on evidence, opinion, or both. as best viewed in their entirety, rather than in Even when guidelines were based on opinion, their component parts. that opinion is supported by direct or extrapo• There is a paucity of data on children in the lated evidence. areas covered by these guidelines. Pediatricians These guidelines are intended for use by health were represented on the Work Group, and outside care professionals trained to understand varia• pediatric consultations were obtained. Because tions in the practice of medicine and the necessity some recommendations for adults do not apply to for such variation. These guidelines are not in• children, additional recommendations are included tended for punitive use by any oversight official when appropriate for pediatric patients. For the who does not understand the reasons or the ne• cessity for practice variations including varia• © 1997 by the National Kidney Foundation, Inc. tions in societies different from that of the United 0272·6386/97/3003-0210$3.00/0 States. AmericanJournal of Kidney Diseases, Vol 30, No 3, Suppl 2 (September), 1997: p S69 S69 I. Initiation of Dialysis BACKGROUND or peritoneal). Hence, it is likely that delays in referral for initiation of dialysis result in unneces• sary morbidity and potentially higher costs as Two clinical guidelines for when to initiate well. While seeing a nephrologist does not guar• dialysis are provided because there appear to be antee that patients will be adequately prepared two independent predictors of clinical outcome. and referred for dialysis, it dramatically increases The first guideline is based on the level of renal the likelihood that this will occur. 13 function (as measured by KrtNurea per week); the second is based on the level of protein intake (as estimated from measured 24-hour urinary urea GUIDELINE 1 nitrogen output and estimated non-urea nitrogen When to Initiate Dialysis-KtlVurea losses). Criterion (Opinion) Although less than I % of American dialysis patients begin dialysis with a serum creatinine Unless certain conditions are met, patients concentration <8.0 mg/dL or a CCr > 10 mLl should be advised to initiate some form of dial• min, approximately 60% suffer from nausea! ysis when the weekly renal KtNurea (KrtNurea ) vomiting at the time of dialysis initiation.3 Thus, falls below 2.0. The conditions that may indicate the likelihood of malnutrition in this population dialysis is not yet necessary even though the is high. Evidence from the Modification of Diet weekly KrtNurea is less than 2.0 are: in Renal Disease (MDRD) studl and a recent 1. Stable or increased edema-free body large Australian study5 clearly show that when weight. Supportive objective parameters for ade• glomerular filtration rate (GFR) decreases to 25 quate nutrition include a lean body mass >63%, to 50 mL/min, patients adapt by reducing their subjective global assessment score indicative of protein intake. Protein intake continues to decline adequate nutrition (see Guideline 12: Nutritional as renal disease progresses to end stage. These Status Assessment and Appendix B: Detailed Ra• observations have been corroborated in a pro• tionale for Guideline 2) and a serum albumin spective study.6 As renal function deteriorates, concentration in excess of the lower limit for the protein and energy intake decreases, leading to lab, and stable or rising; and changes in body weight, fat mass, serum albu• 2. nPNA ~0.8 g/kg/d (see Guideline 2: When min, and transferrin concentrations. Earlier initi• To Initiate Peritoneal Dialysis-nPNA Criteria ation of dialysis may prevent or perhaps even and Appendix B: Detailed Rationale for Guide• reverse this deterioration in nutritional status. In• line 2); and creased serum albumin concentration has been 3. Complete absence of clinical signs or shown to parallel the increase in KtNurea for HD symptoms attributable to uremia. patients.7 In addition, an editorial review cited A weekly KrtNurea of2.0 approximates a renal data8 suggesting that albumin level at initiation urea clearance of 7 mL/min and a renal creatinine of dialysis is predictive of survival.9 clearance that varies between 9 to 14 mL/mini 2 Adverse clinical and economic consequences 1.73 m • Urea clearance should be normalized of failure to properly manage patients as they to total body water (V) and creatinine clearance 2 approach ESRD and dialysis were first described should be expressed per 1.73 m of body surface in Britain.1O These observations have now been area. The GFR, which is estimated by the arith• corroborated in other regions of Britain, the metic mean of the urea and creatinine clearances, 2 United States, and France. Jl·14 Specifically, costs, will be approximately 10.5 mLiminl1.73 m hospitalization, and morbidities decrease if atten• when the KrtNurea is about 2.0. tion is paid to nutrition, acid-base status, hypo• Rationale A detailed rationale is described in calcemia, hyperphosphatemia, anemia, hyperten• Appendix A. The following is a summary. sion, volume status, and dialysis access (vascular It is paradoxical that nephrologists have fo• cused on optimizing urea clearance once patients are started on dialysis, but have accepted much © 1997 by the National Kidney Foundation, Inc. lower levels of renal urea clearance during the 0272-6386/97/3003-0211 $3.00/0 pre-dialysis phase of patient management. For· S70 AmericanJournal of Kidney Diseases, Vol SO, No 3, Suppl 2 (September), 1997: pp S70-S73 INITIATION OF DIALYSIS S71 example, a weekly total (residual renal plus peri• (see Guidelines 3: Frequency of Delivered PD toneal dialysis) KtlVurea(KprtlVurea) of 2.0 or Dose and Total Solute Clearance Measurement higher is associated with improved outcomes in Within Six Months of Initiation and Guideline patients on PD (see Guideline 15: Weekly Dose 5: Frequency of Measurement of KtlVure .. Total of CAPD), yet dialysis is usually not initiated CCr, PNA, and Total Creatinine Appearance).
Recommended publications
  • Cefoxitin Versus Piperacillin– Tazobactam As Surgical Antibiotic Prophylaxis in Patients Undergoing Pancreatoduodenectomy: Protocol for a Randomised Controlled Trial
    Open access Protocol BMJ Open: first published as 10.1136/bmjopen-2020-048398 on 4 March 2021. Downloaded from Cefoxitin versus piperacillin– tazobactam as surgical antibiotic prophylaxis in patients undergoing pancreatoduodenectomy: protocol for a randomised controlled trial Nicole M Nevarez ,1 Brian C Brajcich,2 Jason Liu,2,3 Ryan Ellis,2 Clifford Y Ko,2 Henry A Pitt,4 Michael I D'Angelica,5 Adam C Yopp1 To cite: Nevarez NM, ABSTRACT Strengths and limitations of this study Brajcich BC, Liu J, et al. Introduction Although antibiotic prophylaxis is Cefoxitin versus piperacillin– established in reducing postoperative surgical site tazobactam as surgical ► A major strength of this study is the multi- infections (SSIs), the optimal antibiotic for prophylaxis in antibiotic prophylaxis institutional, double- arm, randomised controlled in patients undergoing pancreatoduodenectomy (PD) remains unclear. The study trial design. objective is to evaluate if administration of piperacillin– pancreatoduodenectomy: ► A limitation of this study is that all perioperative care protocol for a randomised tazobactam as antibiotic prophylaxis results in decreased is at the discretion of the operating surgeon and is controlled trial. BMJ Open 30- day SSI rate compared with cefoxitin in patients not standardised. 2021;11:e048398. doi:10.1136/ undergoing elective PD. ► All data will be collected through the American bmjopen-2020-048398 Methods and analysis This study will be a multi- College of Surgeons National Surgical Quality ► Prepublication history for institution, double- arm, non- blinded randomised controlled Improvement Program, which is a strength for its this paper is available online. superiority trial. Adults ≥18 years consented to undergo PD ease of use but a limitation due to the variety of data To view these files, please visit for all indications who present to institutions participating included.
    [Show full text]
  • Extraneal PI Brunei.Pdf
    BAXTER EXTRANEAL Peritoneal Dialysis Solution The drained fluid should be inspected for the presence of fibrin or cloudiness, with 7.5% Icodextrin which may indicate the presence of peritonitis. For intraperitoneal administration only Safety and effectiveness in pediatric patients have not been established. Protein, amino acids, water-soluble vitamins, and other medicines may be lost PATIENT LEAFLET during peritoneal dialysis and may require replacement. Peritoneal dialysis should be done with caution in patients with: Product name 1) abdominal conditions, including disruption of the peritoneal membrane and EXTRANEAL (Icodextrin 7.5%) diaphragm by surgery, from congenital anomalies or trauma until healing is complete, abdominal tumors, abdominal wall infection, hernias, fecal Composition fistula, colostomy, or ileostomy, frequent episodes of diverticulitis, EXTRANEAL is a sterile solution for intraperitoneal administration. inflammatory or ischemic bowel disease, large polycystic kidneys, or other conditions that compromise the integrity of the abdominal wall, abdominal Each 100 ml of EXTRANEAL contains: Electrolyte solution content per 1000 ml: surface, or intra-abdominal cavity; and Icodextrin 7.5 g Sodium 132 mmol 2) other conditions including aortic graft placement and severe pulmonary Sodium Chloride 538 mg Calcium 1.75 mmol disease. Patients should be carefully monitored to avoid over- and underhydration, Sodium Lactate 448 mg Magnesium 0.25 mmol which may have severe consequences including congestive heart failure, Calcium Chloride 25.7 mg Chloride 96 mmol volume depletion and shock. An accurate fluid balance record should be kept and the patient’s body weight monitored. Magnesium Chloride 5.08mg Lactate 40 mmol Overinfusion of an EXTRANEAL volume into the peritoneal cavity may be Theoretical osmolarity 284 (milliosmoles per litre).
    [Show full text]
  • Guidelines for Contributing Authors
    Charuhas V. Thakar, MD, FASN, FNKF Editor-in-Chief Professor of Medicine Director, Division of Nephrology Kidney C.A.R.E. Program (Clinical Advancement, Research & Education) 231 Albert B Sabin Way Cincinnati, OH 45267 Email: [email protected] Phone: 513-558-5471 Samantha Kramer, Managing Editor Email: [email protected] Guidelines for Contributing Authors Mission Statement The purpose of Advances in Chronic Kidney Disease (ACKD) is to provide in-depth, scholarly review articles about the care and management of persons with early kidney disease and kidney failure, as well as those at risk for kidney disease. Emphasis is on articles related to the early identification of kidney disease; prevention or delay in progression of kidney disease; the multidisciplinary case management of patients with chronic kidney disease or kidney failure; organ effects of kidney disease; epidemiology and outcomes research in kidney disease; benefits and complications of the primary treatment methods, dialysis and transplantation; technical aspects of the delivery of uremia therapy; care of the critically ill patient with kidney failure in the intensive care setting; new therapies for kidney failure; and health care research in chronic kidney disease. The full spectrum of basic science through clinical care is covered in these reviews. Clinical care issues stress the multidisciplinary team approach to the care of kidney patients. Topics covered will be of interest to practicing nephrologists (pediatric and adult), nephrology fellows (pediatric and adult), nurses, technicians, dieticians, and social workers caring for patients with kidney disease. Each issue of ACKD includes a focused review section of several articles on a topic of current interest.
    [Show full text]
  • Traumatic Haemoabdomen
    Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2010 Traumatic haemoabdomen Sigrist, Nadja ; Spreng, D Abstract: Haemoabdomen is an important differential diagnosis for canine and feline abdominal trauma. The diagnosis is made by aspiration of blood from the abdomen by abdominocentesis. Spleen and liver are the most likely sources of traumatic bleeding. Patients are stabilized with appropriate fl uid therapy, oxygen supplementation and analgesia. With ongoing haemorrhage, serial measurement of abdominal and venous haematocrit can be helpful in making the decision between surgical and medical therapy. Most patients with traumatic haemoabdomen can be treated medically. Surgical therapy should be reserved for patients that cannot be stabilized despite medical intervention. The surgical approach should be thoroughly planned in order to minimize further abdominal blood loss and blood transfusions should be readily available. Posted at the Zurich Open Repository and Archive, University of Zurich ZORA URL: https://doi.org/10.5167/uzh-123588 Journal Article Published Version Originally published at: Sigrist, Nadja; Spreng, D (2010). Traumatic haemoabdomen. European Journal of Companion Animal Practice (EJCAP), 20(1):45-52. CRITICAL CARE REPRINT PAPER (CH) Traumatic Haemoabdomen N. Sigrist(1), D. Spreng(1) SUMMARY Traumatic haemoabdomen Haemoabdomen is an important differential diagnosis for canine and feline abdominal trauma. The diagnosis is made by aspiration of blood from the abdomen by abdominocentesis. Spleen and liver are the most likely sources of traumatic bleeding. Patients are stabilized with appropriate fl uid therapy, oxygen supplementation and analgesia. With ongoing haemorrhage, serial measurement of abdominal and venous haematocrit can be helpful in making the decision between surgical and medical therapy.
    [Show full text]
  • Abbreviations
    Abbreviations AAPCC Adjusted average per capita cost CKD-EPI chronic kidney disease epidemiology calculation ACEI angiotensin-converting enzyme inhibitor CKO cytokinin oxidase ACR albumin/creatinine ratio CMS Centers for Medicare & Medicaid Services ADL activities of daily living CMV cytomegalovirus (antibody status) ADR annual data report COPD chronic obstructive pulmonary disease AF atrial fibrillation CORR Canadian Organ Replacement Register AFIB atrial fibrillation CPM clinical performance measures AFS Annual Facility Survey (CMS 2744) CPRA calculated panel reactive bodies AJKD American Journal of Kidney Disease CPT current procedure and terminology AKI acute kidney injury CrCl creatinine clearance rate AKI-D acute kidney injury with dialysis CROWNWeb Consolidated Renal Operations in a Web- AMI acute myocardial infarction Enabled Network (CROWN) Data — data collection system for ESRD dialysis ANZDATA Australia & New Zealand ESRD database facilities mandated by CMS ARB angiotensin receptor blocker CRT cardiac resynchronization ASHD atherosclerotic heart disease CVA cerebrovascular accident AV arteriovenous CVD cardiovascular disease BMI body mass index CVVHD continuous venous-to-venous hemodialysis BUN blood urea nitrogen CWF common working file CABG coronary artery bypass grafting DCD donation after circulatory death CAPD continuous ambulatory peritoneal dialysis DCI Dialysis Clinic, Inc. CBC complete blood count DFC dialysis facility compare CCPD continuous cycling peritoneal dialysis DGF delayed graft function CDC Centers for Disease
    [Show full text]
  • Cystatin C and Some Biochemical Parameters for Dialysis Adequacy Among Hemodialysed Patients at Al-Shifa Hospital, Gaza-Governorate
    الجامعةةةةةةةةةةةةةةةةةةةةة اﻹسةةةةةةةةةةةةةةةةةةةة مية بغةةةةةةةةةةةةةةةةةةةة زة The Islamic University of Gaza عمةةةةةةاحة البحةةةةةةد العلمةةةةةةي والد اسةةةةةةا العليةةةةةةةا Deanship of Research and Graduate Studies كليةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةة العلةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةو Faculty of Science Master of Biological Sciences ماجسةةةةةةةةةةةةةةةةةةتير العلةةةةةةةةةةةةةةةةةةو الحياتيةةةةةةةةةةةةةةةةةةةة Medical Technology التحةةاليةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةل الطبيةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةة Cystatin C and Some Biochemical Parameters for Dialysis Adequacy Among Hemodialysed Patients at Al-Shifa Hospital, Gaza-Governorate سيستاتين سي وبعض المعايير البيوكيميائية لقياس كفاءة الغسيل الدموي لدى مرضى الفشل الكلوي المزمن في مستشفى الشفاء - محافظة غزة Prepared By Fawwaz H. Eliglah Supervisor Prof. Baker M. Zabut Faculty of Science Biochemistry Department The Islamic University of Gaza A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science in Biological Sciences- Medical Technology September , 2018 إقةةةةةةةةةةةةةةرا أنا الموقع أحناه مقد الرسالة التي تحمل العنوان: Cystatin C and Some Biochemical Parameters for Dialysis Adequacy Among Hemodialysed Patients at Al-Shifa Hospital, Gaza-Governorate سيستاتين سي وبعض المعايير البيوكيميائية لقياس كفاءة الغسيل الدموي لدى ي مرضى الفشل الكلو المزمن في مستشفى الشفاء - محافظة غزة أقر بأن ما اشتملت عليه هذه الرسالة إنما هو نتاج جهدي الخاص، باستثناء ما تمت اﻹشارة إليه حيثما ورد، وأن هذه الرسالة ككل أو أي جزء منها لم يقدم من قبل اﻻخرين لنيل درجة أو لقب علمي أو بحثي لدى أي مؤسسة تعليمية أو بحثية أخرى. Declaration I understand the nature of plagiarism, and I am aware of the University’s policy on this. The work provided in this thesis, unless otherwise referenced, is the researcher's own work, and has not been submitted by others elsewhere for any other degree or qualification. اسم الطالب: فواز حسن العجلة :Student's name التوقيع: Signature: Fawwaz H.
    [Show full text]
  • Peritoneal Dialysis in the 21St Century: an Analysis of Current Problems and Future Developments
    J Am Soc Nephrol 13: S104–S116, 2002 Peritoneal Dialysis in the 21st Century: An Analysis of Current Problems and Future Developments RAM GOKAL Manchester Royal Infirmary, Manchester, United Kingdom. One major development in the field of kidney diseases in the of death on PD as compared with HD and by and large found 21st century will be in prevention of end-stage renal disease that mortality risk was equal for HD and PD in the various (ESRD). Basic research has made inroads into the understand- studies reported. After this analysis was the report of Bloem- ing of the mechanisms of progression of chronic renal failure, bergen et al. (2), which was based on the US Renal Data including the understanding of the functions of genes activated Systems (USRDS) data on prevalent patients (1987, 1988, and by renal damage. All this may well result in a major reduction 1989). This showed that PD subjects had a 19% higher risk of in the incidence of ESRD. The second important development mortality as compared with patients who used HD. This was will be in transplantation, which will constitute the mainstay of met with considerable consternation in the United States and ESRD treatment in the next century. The clinical introduction probably did the therapy a major disservice. Analysis from the of xenotransplantation and the cloning of one’s own organs via Canadian Organ Replacement Registry on patients starting one’s stem cells may well represent the major areas of replace- RRT between 1990 and 1994 showed that for incident patients, ment therapy. This will reduce dialysis as a method to support the survival with PD was better in the first 2 yr of treatment the main treatments.
    [Show full text]
  • Antibiotic Prophylaxis in Peritoneal Dialysis Patients
    Advances in Peritoneal Dialysis, Vol. 33, 2017 Antibiotic Prophylaxis in Miten J. Dhruve, Joanne M. Bargman Peritoneal Dialysis Patients Peritonitis is an important cause of morbidity, Discussion mortality, and technique failure in patients on peri- toneal dialysis (PD). The most effective approach Endoscopy in PD patients to peritonitis is prevention, which includes careful Several studies have looked at PD patients undergoing patient training and follow-up. Although peritonitis colonoscopy. Yip et al. (4) reported on 97 colonosco- as a result of contiguous spread of bacteria or fungi pies performed in 77 patients, observing a 6.3% rate of during invasive procedures, or as a result of seeding peritonitis after colonoscopy. Patients who were given of the peritoneum during bacteremia, is uncommon, prophylactic antibiotics did not develop colonoscopy- the likelihood of such spread is often predictable, and related peritonitis. The authors also noted that no in- the risk can be mitigated with antibiotic prophylaxis. crease in the rate of peritonitis was observed in patients Here, we describe the rationale for, and approach to, who underwent polypectomy. Wu et al. (5) reported a antibiotic prophylaxis in PD patients for the preven- similar post-endoscopy peritonitis rate of 6.4% and tion of infective episodes. noted that no patient prescribed prophylactic antibiot- ics developed peritonitis. In addition, several other Key words small case reports demonstrated the phenomenon of Antibiotics, peritonitis, prevention, bacteremia peritonitis after colonoscopy, with some even reporting a much higher rate of peritonitis (increased by a factor Introduction of 3 – 5) in patients undergoing polypectomy than in Peritonitis is the leading cause of technique failure those having nontherapeutic colonoscopy (5–9).
    [Show full text]
  • Antibiotic Prophylaxis for GI Endoscopy
    GUIDELINE Antibiotic prophylaxis for GI endoscopy This is one of a series of statements discussing the use of procedure. Endoscopy-related bacteremia carries a small GI endoscopy in common clinical situations. The Stan- risk of localization of infection in remote tissues (ie, infec- dards of Practice Committee of the American Society for tive endocarditis [IE]). Endoscopy also may result in local Gastrointestinal Endoscopy (ASGE) prepared this docu- infections in which a typically sterile space or tissue is ment, and it updates a previously issued document on breached and contaminated by an endoscopic accessory this topic.1 In preparing this guideline, MEDLINE and or by contrast material injection. This document is an up- PubMed databases were used to search for publications date of the prior ASGE document on antibiotic prophylaxis between January 1975 and December 2013 pertaining for GI endoscopy,1 discusses infectious adverse events to this topic. The search was supplemented by accessing related to endoscopy, and provides recommendations for the “related articles” feature of PubMed, with articles periprocedural antibiotic therapy. identified on MEDLINE and PubMed as the references. Additional references were obtained from the bibliogra- phies of the identified articles and from recommenda- BACTEREMIA ASSOCIATED WITH tions of expert consultants. When few or no data were ENDOSCOPIC PROCEDURES available from well-designed prospective trials, emphasis was given to results from large series and reports from Bacteremia can occur after endoscopic procedures and has been advocated as a surrogate marker for IE risk. How- recognized experts. Weaker recommendations are indi- fi cated by phrases such as “We suggest.” whereas stronger ever, clinically signi cant infections are extremely rare.
    [Show full text]
  • Manual of Clinical Dialysis
    Manual of Clinical Dialysis Second Edition Manual of Clinical Dialysis Second Edition Suhail Ahmad University of Washington, Scribner Kidney Center, Northwest Kidney Centers, Seattle, Washington, USA ABC Suhail Ahmad, MD Professor, Medicine University of Washington Scribner Kidney Center Northwest Kidney Centers Seattle, Washington [email protected] ISBN: 978-0-387-09650-6 e-ISBN: 978-0-387-09651-3 DOI: 10.1007/978-0-387-09651-3 Library of Congress Control Number: 2008928866 °c Springer Science+Business Media, LLC 2009 All rights reserved. This work may not be translated or copied in whole or in part without the written permission of the publisher (Springer Science+Business Media, LLC, 233 Spring Street, New York, NY 10013, USA), except for brief excerpts in connection with reviews or scholarly analysis. Use in connection with any form of information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed is forbidden. The use in this publication of trade names, trademarks, service marks, and similar terms, even if they are not identified as such, is not to be taken as an expression of opinion as to whether or not they are subject to proprietary rights While the advice and information in this book are believed to be true and accurate at the date of going to press, neither the authors nor the editors nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein. Printed on acid-free paper springer.com Grateful thanks to my family, Vimli, Saba, and Zeba, and friends for their strong support and to Arlene for all of her help.
    [Show full text]
  • Peritoneal Dialysis: What You Need to Know What Is Peritoneal Dialysis? Peritoneal Dialysis (PD) Is a Treatment for People Who Have Kidney Failure
    Peritoneal Dialysis: What You Need to Know What is peritoneal dialysis? Peritoneal dialysis (PD) is a treatment for people who have kidney failure. Kidney failure is stage five of chronic kidney disease (CKD). Healthy kidneys clean wastes from blood and remove extra fluid from the body. But when your kidneys are not working well, wastes and extra fluid can build up in your blood and make you sick. This can cause: ■ nausea ■ trouble sleeping ■ poor appetite ■ loss of energy ■ hiccups ■ dry, itchy skin ■ weight loss ■ irregular menstrual periods ■ muscle cramping, especially at night ■ swelling ■ anemia (low blood count) ■ trouble breathing Why do I need peritoneal dialysis? You need treatment because your kidneys no longer clean enough wastes from your blood and remove extra fluid from your body. Even though people with kidney failure may still have some kidney function, it's not enough and without treatment you will die. 2 NATIONAL KIDNEY FOUNDATION TIP You should do all you can to protect any kidney function you have left. Studies show that remaining kidney function helps dialysis patients stay healthier and live longer. Ask your dialysis care team about the following steps to help keep or enhance your remaining kidney function: ■ Taking blood pressure pills called ACEs (angiotensin converting enzyme inhibitors) or ARBs (angiotensin receptor blockers) if you have high blood pressure. These medicines help to protect kidney function. ■ Avoiding medicines that can harm your kidneys such as pain relieving medicines called NSAIDs (nonsteroidal anti-inflam- matory drugs) and certain antibiotics. ■ Taking diuretics (water pills) to help remove salt and water from your blood.
    [Show full text]
  • Kt/V Calculations for the Assessment of Hemodialysis Adequacy
    Wt 0.10 0.08 0.06 0.04 1.80 0.02 0.00 1.60 1.40 Kt/V 1.20 1.00 0.80 0.60 0.40 0.50 0.60 0.70 0.80 URR We have found that the Keshaviah Quick Kt/V formula most closely correlates with both of the more complex Kt/V calculations that Spectra offers - the Daugirdas II Natural Log and Depner Full UKM Kt/V (see Figures 2 & 3). Comparison of Kt/V Formulas to UKM Kt/V Comparison of Kt/V Formulas to UKM Kt/V 1500 Patient Results 0.6 to 2.0 2.20 2.20 2.00 2.00 1.80 1.80 1.60 1.60 1.40 1.40 1.20 Kt/V Calculations for 1.00 1.20 0.80 1.00 0.60 the Assessment of 0.40 1 4 7 0.80 17 19 21 23 25 27 29 31 33 35 37 39 41 43 45 47 49 51 53 55 57 59 61 63 65 67 69 71 73 75 77 79 81 83 85 87 89 91 93 95 97 99 101 103 105 107 109 111 113 115 117 10 13 16 19 22 25 28 31 34 37 40 43 46 49 52 55 58 61 64 67 70 73 76 79 82 85 88 91 94 97 112 115 118 100 103 106 109 121 Hemodialysis Adequacy Depner Full UKM Depner Full UKM Daugirdas II (Post BUN/Pre BUN-0.008 x t) + Daugirdas II (Post BUN/Pre BUN-0.008 x t) + Natural Log [4-3.5 x (Post BUN/Pre BUN)] x UF / Wt Natural Log [4-3.5 x (Post BUN/Pre BUN)] x UF / Wt Jindal 0.04*URR-1.2 Jindal 0.04*URR-1.2 Basile 0.023*URR-0.284 Basile 0.023*URR-0.284 Depner 0.026*URR-0.49 Depner 0.026*URR-0.49 Keshaviah 1.162*In(Pre/Pst) Keshaviah 1.162*In(Pre/Pst) Figure 2 Figure 3 References 1 Daugirdas JT: Second generation logarithmic estimates of single-pool variable volume Kt/V: An analysis of error.
    [Show full text]